Biogen enhances its portfolio and margins amidst market challenges and competition. Click here to find out why BIIB stock is ...
Fintel on MSN3d
Maxim Group Downgrades CNS Pharmaceuticals (CNSP)Fintel reports that on March 25, 2025, Maxim Group downgraded their outlook for CNS Pharmaceuticals (NasdaqCM:CNSP) from Buy ...
Berubicin showed clinically relevant outcomes comparable to Lomustine across multiple endpoints, but not a statistically significant difference in overall survival, the primary endpoint.The safety pro ...
The company also continues development of a ... complete response in a Phase 1 human clinical trial conducted by Reata Pharmaceuticals, Inc. Berubicin was developed by Dr. Waldemar Priebe ...
At last week's JPMorgan conference, Biogen chief executive Chris Viehbacher said the company is open to additional bolt-on acquisitions, like its 2023 purchase of Reata Pharma and its rare disease ...
Aduhelm’s demise, and an expected slow take-up of Leqembi, came as the company’s longstanding ... of a planned $7.3 billion takeover of Reata Pharma, aimed at bolstering its product portfolio ...
Milestone Pharmaceuticals said on Friday the U.S. health regulator had declined to approve its nasal spray to treat a type of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback